( July 1, 2025, 2:02 PM EDT) -- NEWARK, N.J. — Novo Nordisk’s opposition to a motion to dismiss “does nothing to change the fact that its causes of action remain insufficiently pled under” Ashcroft v. Iqbal and Bell Atlantic Corp. v. Twombly, an aesthetic medical practice facing allegation that it improperly markets and sells compounded drug products that purport to contain semaglutide says in its June 30 reply brief....